FDA Approves First Generic of Popular Blood Thinner
The first generic versions of the powerful blood thinner Eliquis (apixaban) were approved by the U.S. Food and Drug Administration on Monday.
“Today’s approvals of the first generics of apixaban are an example of how the FDA’s generic drug program improves access to lower-cost, safe and high-quality medicines,” Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, said in an agency news release.
“These approvals mark the first generic approvals of a direct oral anticoagulant,” Woodcock noted. “Direct oral anticoagulants [blood thinners] do not require repeated blood testing.”
The two types of generic tablets were approved to reduce the risk of stroke and systemic clotting in the lungs of patients with non-valvular atrial fibrillation and for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (lung clots), in patients who have had hip or knee replacement surgery.
Atrial fibrillation is a heart rhythm disorder that raises the risk of blood clots. It is estimated that between almost 3 and 6 million Americans have atrial fibrillation, according to the U.S. Centers for Disease Control and Prevention. Many of these individuals use anticoagulants or anti-clotting drugs to reduce that risk, the FDA noted.
There is an increased risk of blood clots forming inside a blood vessel, or strokes, if a patient stops using apixaban too early, the agency said.
Patients with prosthetic heart valves should not take apixaban nor should patients with atrial fibrillation that is caused by a heart valve problem. As with other approved anti-clotting drugs, bleeding, including life-threatening and fatal bleeding, is the most serious risk with apixaban.
The generic apixaban approvals were granted to Micro Labs Limited and Mylan Pharmaceuticals Inc.
Brief About Taj Generics:
Life is the underlying purpose of everything we do at Taj Generics – Taj Pharma Group. We are committed to developing a distinguished generics pharmaceuticals business. A purpose that defines our R & D strategy of discovering & developing innovative products that improve the quality of life.
Taj Pharma is one of the leading generic pharmaceutical company in India. We hold top positions in different established markets worldwide and are building a strong presence in many emerging generics markets. Today, we market more than 500 branded and 4600 generics compositions to consumers in more than 40 countries and territories across the globe. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. Our deep customer relationships, quality medicines and consistently delivered promise make us a trusted brand across the world.
Labels: Blood thinner , generic version, generic medicines information